FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3049203364> ?p ?o ?g. }

• W3049203364 abstract "<h3>Background</h3> Nesfatin-1 is actively studied in the pathogenesis of metabolic disorders. An excess of this factor in the brain leads to loss of appetite, a feeling of fullness, as well as a decrease in body weight. Similarly, elevated levels of nesfatin are associated with depressive disorders [1]. We studied the level of nesfatin in the serum of patients with rheumatoid arthritis (RA) and found a relationship with systemic inflammation and functional impairment [2]. <h3>Objectives</h3> To study the relationship of serum nesfatin-1 levels with the clinical manifestations of RA. <h3>Methods</h3> To identify the relationship between serum nesfatin-1 and the clinical manifestations of rheumatoid arthritis, all patients were divided into 2 groups. The first group - 1 (66 patients) with elevated serum nesfatin (> 37.95 ng/ml). The second group - 2 (44 patients) - with normal values (<37.95ng/ml). In both groups, we studied the clinical manifestations of RA. <h3>Results</h3> A high level of nesfatin in RA patients was typical for patients with a higher degree of activity in DAS28 (χ2 = 8.37; p = 0.04), seropositivity for the rheumatoid factor (RF) - (χ2 = 5.53; p = 0, 02), the duration of the disease is more than 10 years (χ2 = 9.53; p = 0.01). At the same time, there was no significant correlation between the level of nesfatin and the extra-articular manifestations of RA (χ2 = 2.09; p = 0.14) and the degree of radiological damage to the joints (χ2 = 4.45; p = 0.21). <h3>Conclusion</h3> This study shows that serum Nesfatin-1 levels are significantly higher in patients with more unfavorable RA, than in RA with minimal clinical manifestations. These data confirm the pathogenetic role of Nesfatin-1 in the development of clinical manifestations associated primarily with RA activity, but to a lesser extent with organ lesions in RA. The relationship of the level of nesfatin with the duration of the disease is of particular interest, since there is no correlation with the degree of X-ray damage to the joints and organ damage. There are literary data on the relationship of depression and late stage of RA [3]. <h3>References</h3> [1] Role of nesfatin-1 in anxiety, depression and the response to stress/Weibert E, Hofmann T, Stengel A//Psychoneuroendocrinology. 2018; 29;100:58-66. doi: 10.1016/j.psyneuen.2018.09.037. [2] Elevated Nesfatin-1 levels in patients with Rheumatoid Arthritis/T.Z. Kvlividze, B.V. Zavodovsky, Y.R. Akhverdyan, L.E. Sivordova, Y.V. Polyakova, D.P. Lavrova, A.T. Yakovlev//Ann Rheum Dis, V.77, Suppl, 2018, P. A1762 [3] Waheed A., Hameed K., Khan A.M. et al. The burden of anxiety and depression among patients with chronic rheumatologic disorders at a tertiary care hospital clinic in Karachi, Pakistan//J Pak Med Assoc2006; 56: 243–7. <h3>Disclosure of Interests</h3> None declared" @default.
• W3049203364 created "2020-08-21" @default.
• W3049203364 creator A5007513249 @default.
• W3049203364 creator A5032586058 @default.
• W3049203364 creator A5035800884 @default.
• W3049203364 creator A5090401230 @default.
• W3049203364 date "2019-05-27" @default.
• W3049203364 modified "2023-10-14" @default.
• W3049203364 title "AB0070 THE RELATIONSHIP BETWEEN THE LEVEL OF NESFATIN-1 AND THE CLINICAL MANIFESTATIONS OF RHEUMATOID ARTHRITIS" @default.
• W3049203364 doi "https://doi.org/10.1136/annrheumdis-2019-eular.1564" @default.
• W3049203364 hasPublicationYear "2019" @default.
• W3049203364 type Work @default.
• W3049203364 sameAs 3049203364 @default.
• W3049203364 citedByCount "0" @default.
• W3049203364 crossrefType "proceedings-article" @default.
• W3049203364 hasAuthorship W3049203364A5007513249 @default.
• W3049203364 hasAuthorship W3049203364A5032586058 @default.
• W3049203364 hasAuthorship W3049203364A5035800884 @default.
• W3049203364 hasAuthorship W3049203364A5090401230 @default.
• W3049203364 hasBestOaLocation W30492033641 @default.
• W3049203364 hasConcept C126322002 @default.
• W3049203364 hasConcept C134018914 @default.
• W3049203364 hasConcept C198451711 @default.
• W3049203364 hasConcept C2776232647 @default.
• W3049203364 hasConcept C2776914184 @default.
• W3049203364 hasConcept C2777077863 @default.
• W3049203364 hasConcept C2777575956 @default.
• W3049203364 hasConcept C2780942790 @default.
• W3049203364 hasConcept C71924100 @default.
• W3049203364 hasConcept C90924648 @default.
• W3049203364 hasConceptScore W3049203364C126322002 @default.
• W3049203364 hasConceptScore W3049203364C134018914 @default.
• W3049203364 hasConceptScore W3049203364C198451711 @default.
• W3049203364 hasConceptScore W3049203364C2776232647 @default.
• W3049203364 hasConceptScore W3049203364C2776914184 @default.
• W3049203364 hasConceptScore W3049203364C2777077863 @default.
• W3049203364 hasConceptScore W3049203364C2777575956 @default.
• W3049203364 hasConceptScore W3049203364C2780942790 @default.
• W3049203364 hasConceptScore W3049203364C71924100 @default.
• W3049203364 hasConceptScore W3049203364C90924648 @default.
• W3049203364 hasLocation W30492033641 @default.
• W3049203364 hasOpenAccess W3049203364 @default.
• W3049203364 hasPrimaryLocation W30492033641 @default.
• W3049203364 hasRelatedWork W1978435955 @default.
• W3049203364 hasRelatedWork W1981471379 @default.
• W3049203364 hasRelatedWork W1992274911 @default.
• W3049203364 hasRelatedWork W2023721760 @default.
• W3049203364 hasRelatedWork W2097436305 @default.
• W3049203364 hasRelatedWork W2099861443 @default.
• W3049203364 hasRelatedWork W2412341873 @default.
• W3049203364 hasRelatedWork W2571511046 @default.
• W3049203364 hasRelatedWork W3163904099 @default.
• W3049203364 hasRelatedWork W4290989979 @default.
• W3049203364 isParatext "false" @default.
• W3049203364 isRetracted "false" @default.
• W3049203364 magId "3049203364" @default.
• W3049203364 workType "article" @default.